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Abstract
These investigations demonstrate that serum antibodies against muscarinic acetylcholine receptors (mAChR) in 
primary Sjögren syndrome (pSS) and associated Sjögren syndrome (aSS) bind and activate both cholinergic receptors 
of M3 in salivary gland and M1 in neonatal myocardium and in the cerebral frontal cortex area subtypes; triggering the 
production of the second messengers and proinflammatory mediators related to mAChR activation. In this way the 
cholinergic autoantibodies damages these receptors, which thus starts acting as an antigen. On this basis M3 and M1 
mAChR IgG can be considered new markers of pSS/aSS allowing the differentiation between dry eye and mouth of 
autoimmune and non-autoimmune nature. Given that cholinergic autoantibodies also deregulate the parasympathetic 
system of the target organs, they can also be seen as a new factor contributing to the etiopathology of the syndrome.
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Introduction
Sjögren syndrome (SS) is a devastating autoimmune illness with 
heterogeneous clinical expressions. These expressions reflect not 
only different etiologic factors, e.g. genetically and immunological 
abnormalities, but also the deregulation among them as well as the 
dysfunction of the parasympathetic system. They have the following 
cardinal clinical symptoms: xerostomia and xerophtalmia at the level 
of the exocrine glandular system [1], cognitive impairments such as 
perception, attention and executive function deficits [2] at the level of 
the cerebral frontal cortex, complete congenital heart block at the level 
of neonatal myocardium [3]. These alterations are reliable predictors of 
long term disabilities. 
Numerous theories have been formulated and tested and continue 
to compete for supremacy as the essential explanation for why patients 
suffer from periodic episodes of altered exocrine secretion and 
remission and why these episodes typically result in same social and 
cognitive dysfunction in the chronic course of the SS. Relevant in this 
sense, are those theories shifting their attention to the organ specific 
immunological deregulation involved in the manifestations and the 
chronic course of the disease [4-7], and to the clinical features of an 
immunological or inflammatory disease [8,9].
In this line, anti-salivary/frontal antibodies have been shown to 
be involved in autoimmune disorders with cognitive manifestations in 
lupus [10] and in SS [11]. It should be noted that the main autoantibody 
involved in these disorders are the mAChR subtype M3 and M1 [11].
In this article we will examine the role of cholinergic autoantibodies 
subtypes M3 and M1 and its relationship with the signs and symptoms of 
SS and its pathological implications in SS.
Autoimmune Basis of Sjögren Syndrome
Primary SS occurs in 0.1 to 3.0% of the population in general.The 
disease is more common among women (female/male ratio 9:1) aged 40 
to 60 years old and is rarely seen in children and adolescents.
There are many factors to be considered in the etiology of the 
disease such as genetic factors in which the B cell [12] or the B-cell 
activation factor (BAFF) and the tumor necrosis factor (TNF) are 
implicated. Furthermore, it is presumed that the genetic predisposition 
leading to the increment of type I IFN may explain why this interferon 
is present in the salivary gland and peripheral blood in pSS patients. 
HLA-B8 of HLA-DW3, HLA-DR3 and DRW52 have also been 
reported in pSS patients [13,14]. Other factors responsible for the 
development of pSS are viral infections -mainly, Epstein-Barr virus 
(EBV), cytomegalovirus (CMV) and Hepatitis C virus (HCV) [15]; 
neurohormonal disturbances in sex hormones [16]; environmental 
factors causing the disorganization of glandular epithelial cells, which 
provoke local innate immune response and activate the toll-like 
receptor (TLR) pathway involving cell apoptosis [5]; the stimulation of 
the dendritic cells responsible for the production of INF, which, in turn, 
leads to the proliferation and the differentiation of B cells and to the 
production of autoantiboidies.
Nowadays autoimmunity is recognized as a very important factor 
responsible for the development of the disease [17,18]. In this line, oral 
and eye sicca symptoms provoking a decrease of the exocrine glandular 
function are taken as evidence of autoimmunity with the presence of 
autoantibodies to Ro/SS-A (Ro52, Ro60) or La/SS-B [19,20]. These 
autoantibodies are non organ specific and their role in the pathogenesis 
of SS was not been understood yet. Some explanations suggest that 
Ro60 and La autoantigen unlike Ro52 are involved in triggering and 
maintaining the tissue specific autoimmune response in pSS. This 
indicates that Ro60 and La autoantigens contribute to the antigen driven 
immune response and to the production of these autoantibodies. This 
idea is supported by a further research that documents the production of 
local anti Ro system and anti La autoantibody in the submandibular and 
parotid gland of pSS patients [21]. Subsequent studies [22] demonstrate 
that lymphocytes’ infiltration in salivary gland is organized in the 
form of an ectopic germinal centre, in which anti-Ro60, anti-Ro52 
and anti La autoantibodies are produced. They also show that these 
autoantibodies participate in the cell apoptosis [22]. The sustenance of 
these phenomena in time is responsible for the destruction of the gland 
and other extraglandular manifestations. However, glandular epithelial 
cells are also infiltrated by macrophages, plasma cells, T cells [23] and 
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lacrimal glands M3mAChR, which trigger parasympathetic-receptor-
mediated biological effects [25,39,49,50]. We have demonstrated that 
they are able to recognize a synthetic peptide corresponding in amino 
acid sequence to the second extracellular loop of the human M3mAChR. 
The distribution of the amino acid sequence between rat and human 
M3 synthetic peptide has a great homology (84%). An isolated fraction 
from SSIgG enriched in anti-M3 peptide antibodies could reproduce 
the effects of the corresponding whole immunoglobulins. This fact 
strongly suggests a prominent role of anti-M3 peptide antibody in the 
mAChR-mediated effects of total SS IgG. In addition, the synthetic 
peptide involved selectively suppresses the biological effects of SS 
anti-M3 peptide autoantibody and the corresponding total IgG. This 
supports the view that the second extracellular loop is not only the 
main immunogenic region of the receptor [51] but can be considered 
essential for the biological action of these autoantibodies. We also 
demonstrated that there is an association between the existence 
of circulating anti-M3mAChRIgG autoantibodies, the presence of 
ocular and mouth symptoms, gland surface alterations and a selected 
number of antibodies detected in SS. These finding points to these 
autoantibodies as a valuable marker for dry eye and mouth associated 
to SS. In addition, we have shown a good correlation between lacrimal 
function, serum IL-2 receptor, ANA, and RF in SS dry patients [52]. 
This process could lead to a progressive blockade of mAChR which, in 
turn, induces dry eyes and mouth, the classical signs of SS.
Further evidence is required to show persistent abnormal levels 
of IgGs in forebrain tissues of SS patients in order to understand the 
effect of these autoantibodies on the cognitive deficit in these patients. 
Towards this understanding we postulate on the basis of our results that 
the early agonistic-promoting activation of M1 and M3mAChR initiated 
by antibodies bind to cerebral frontal cholinoceptors persistently. 
Later, the agonistic activity displayed by these autoantibodies induces 
desensitization, internalization and/or intracellular degradation of 
the mAChR, leading to a progressive decrease of cerebral M1 and 
M3mAChR expression and activity. Furthermore, IgG antibodies 
binding to mAChRs modify spare receptors’affinity, sensitivity and 
expression in brain tissue. Therefore, it could be hypothesized that 
the central nervous system manifestations, which are apparent during 
SS, might be induced by an impaired response to the cholinergic 
endogenous neurotransmitter’s stimuli due to mAChR-antibody being 
fixed to its receptors [41,53-55].
Antibodies to muscarinic receptors, detected by functional methods 
or the use of synthetic peptides, have been described in SS patients. 
The functions of mAChR M1 and M3 subtypes are numerous, the most 
noteworthy being their function as the main receptors stimulated by 
acetylcholine released by postganglionic fibers in the parasympathetic 
nervous system [56]. It was demonstrated that the agonist-mediated 
stimulation of mAChR M1 and M3 subtypes in rat salivary, lacrimal 
glands leads to saliva and tears production [57]. Subsequent 
studies revealed that they are fundamental for the parasympathetic 
regulation of exocrine secretion [58]. Further functional studies led 
to the assumption that these mAChR M1 and M3 subtypes antibodies 
contribute to sicca manifestations, potentially via direct blockade of 
parasympathetic neurotransmission [17,59].
Fixation of IgG anti M3mAChR autoantibodies of patients with pSS 
has functional implications for the exocrine glands. This is because the 
antibody limits not only parasympathetic stimulation with decreased 
salivary and lacrimal function, but also the effectiveness of endogenous 
agonists [60]. It is well known that the activation of M3mAChR 
generates the secondary messenger’s inositol phosphate (InsP3) and 
dendritic cells [24]. T cells are balanced toward Th1 and Th17, which 
release IL-17 [19] and promote the generation of pro-inflammatory 
cytokines as a main nitric oxide (NO) [25] and as prostaglandins 
(PG) [11]. This is why PGE2 and NO together with IL-6 are seen as 
crucial factors of the maintenance of the inflammatory process and it’s 
becoming chronic [26]. 
It is important to notice that, antinuclear antibodies (ANA) 
together with the rheumatoid factor (RF) and anti centromere antibody 
(ACA) are frequently found in patients with pSS in the early stages of 
the disease and at a younger age [20,27,28]. These antibodies are not 
specific to SS, but in a way, show a local response to autoantigens derived 
from salivary glands aggressors, which produce these antibodies at the 
level of the local system [29].
These immunological events together with histological studies 
of salivary lip glands showing a progressive focal infiltration of 
mononuclear lymphoid cells cause the replacement of the glandular 
epithelial cells and the subsequent reduction of saliva secretion [30,31]. 
In this vein, germinal centre like structures in the gland with elevated 
titres of RF, increased IgG levels and high focus score (FS) equal or 
more than one have been identified [32]. A positive biopsy is then given 
when FS has 50 inflammatory cells in a 4 mm 2 salivary lip glandular 
section [33,34].
Action of Anti-muscarinic Acetylcholine Receptors 
Antibodies in Patients with SS
Experimental and clinical studies suggested the presence of 
cardiac anti-M1mAChR antibodies in mothers with SS whose children 
have congenital heart block [35-39] and the presence of IgG against 
M3mAChR in sera of patients with pSS that interact with rat exorbital 
lacrimal glands [1,25] and rat parotid gland [40]. The presence of IgG 
against M1 and M3mAChR was also found in sera of patients with pSS 
interacting with rat cerebral frontal cortex [41].
Antibodies to neurotransmitter receptors have been described in 
idiopathic dilated myocardiopathy [42] and in chagasicmyocardiopathy 
[43]. The latter is clinically characterized by a dysautonomic syndrome 
related to the progressive blockade of parasympathetic neurotransmitter 
receptors, with a denervation of both adrenergic and cholinergic 
branches of the autonomic nervous system [44]. We described the 
presence of antibodies against cholinergic receptors in cardiac, exocrine 
glands and cerebral frontal cortex in SS and proposed that the deposit 
of these autoantibodies could lead to a progressive blockade of these 
receptors behaving as a partial agonist and inducing desensitization 
and/or down-regulation [45,46].
Thus, Sjögren’s autoantibodies appear to be reactive to the M1 
cholinoceptor ofneonatal heart, suggesting the multiplicity of the 
autoimmune responses in primary SS. Congenital heart block is thought 
to result from the transplacental passage of maternal autoantibodies 
that could cause an inﬂammatory reaction in the developing heart 
of the fetus resulting in severe defects of conduction [47,48]. In this 
regard the hypothesis that cholinoceptor autoantibodies can act as a 
“sensitizing” or “predisposing” condition present at a critical period 
during the development of the fetal electroconduction system seems 
reasonable. Being pSS one of the immune disorders strongly associated 
with congenital heart block, these ﬁndings suggest that M1 muscarinic 
cholinergic autoantibodies are another factor that could be involved in 
the pathogenesis of congenital heart block associated with primary SS in 
addition to ribonucleoprotein antibodies (anti-Ro/SSA and anti-La/SSB).
We have already reported autoantibodies against rat salivary and 
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prostaglandin E2 (PGE2). Each of these metabolites influences salivary 
and lacrimal secretion by mobilising calcium from intracellular stores 
and regulating the absorption of ions and water [61]. They also play a 
key role in the pathophysiology of chronic inflammation [62]. These 
facts have led us to think that the damage and inflammation in the 
exocrine glands commonly seen in SS patients might be a consequence 
of the production of pro-inflammatory mediators induced by antibody-
mAChR interaction on gland membranes.
In the salivary glands, the basal lamina of the acini is connected 
to the cytoskeleton of acinar cells via integrins in the basal plasma 
membrane [63,64]. Matrix metalloproteinase-3 (MMP-3) degrades 
components of the basal lamina [64], and might be involved in the 
loosening of cell anchorage to the basal lamina. As a consequence 
of such changes, inhibition of the proliferation, differentiation and 
regeneration of epithelial cells [65], as well as activation of apoptosis 
[66,67], may account for salivary-gland damage. Patients with pSS show 
elevated levels of MMP-3 in their saliva [68].
Prostaglandins (PGs) have been implicated in normal cellular 
processes as well as in pathophysiological conditions such as 
inflammation [39,69]. Nitric oxide (NO) plays a key part in the 
pathophysiology of chronic inflammation and in the neurodegenerative 
process [38,70-72]. PGE2 is synthesised by cyclooxygenase (COX) and 
prostaglandin E synthase (PGEs) in vivo; the two enzymes catalyse the 
reaction of transformation of arachidonic acid (AA) through PGH2 
into PGE2. The two isoforms of COX (COX-1 and COX-2) and PGEs 
[cytosolic (cPGEs) and membrane (mPGEs)] have been identified. In 
general, COX-1 and cPGEs are constitutively expressed in almost all 
tissues and have haemostatic effects, whereas COX-2 and mPGEs are 
inducible enzymes that are expressed in response to inflammation [73]. 
PGE2 has been shown to be part of the signalling events involved in 
M3mAChR activation [49,71,74].
Previous studies analyzed the role of antibodies using 
microspectrofluorometry and surface the plasmon resonance-based 
optical biosensor system (BIAcore system). They showed that antibodies 
against the third extracellular domain of M3mAChR have an inhibitory 
activity against carbachol-induced calcium influx in human salivary 
gland cell lines [75].
Other authors reported that IgG from patients with pSS reduced the 
expression level of M3mAChR in the membrane, inhibited carbachol-
induced calcium transients in human salivary gland cells and decreased 
membrane clathrin expression. These results suggest that IgG from SS 
patients induce internalization of M3mAChR partly through a clathrin-
mediated pathway. They also provide support to the notion that anti-
mAChR M3 antibodies cause salivary dysfunction in patients with SS 
via both a reduction of calcium influx and the down-regulation of 
M3mAChR molecules on epithelial cells of salivary glands [76].
All these results suggest a complex interplay between different factors 
involved in innate and adaptive immunity, glandular M3/M1mAChR 
and the corresponding release of second messengers provoked by the 
binding and activation of this receptor by the SS autoantibodies. These 
results could also provide a basis to understand the link between auto-
immunity and exocrine parasympathetic dysfunction in SS. This link 
could be further explained by the early agonist-promoting activation 
of salivary and lacrimal gland M3mAChR initiated by autoantibodies 
binding to, and persistently activating cholinoceptors. This result is 
accompanied by the production of large amounts of pro-inflammatory 
substances, contributing to inflammation. The agonist activity 
displayed by anti-M3mAChR peptide antibodies could subsequently 
induce desensitisation, internalisation and/or intracellular degradation 
of glandular M3mAChR. This could lead to a progressive reduction in 
the surface expression and activity of glandular M3mAChR, resulting 
in xerostomy, xerophthalmia and other general and dysautonomic 
parasympathetic symptoms in SS patients.
Influence of Anti-M3 mACHR IgG on Submandibular 
Gland on the Activation and Expression of Nitric Oxide 
Syntase
Methods
Ethical approval of the study protocol: The study protocol complied 
with the tenets of the Declaration of Helsinki and accomplished with 
the rules established by the Ethics Committee of the University of 
Buenos Aires (Buenos Aires, Argentina). All subjects provided written 
informed consent.
Drugs: A 25-mer peptide (K-R-T-V-P-D-N-Q-C-F-I-Q-F-L-S-
N-P-A-V-T-F-G-T-A-I) corresponding to the sequence of the second 
extracellular loop of the human M3 mAChR was synthesized by Peptido 
Genetic Research Company (Livermore, CA, USA) as previously 
described [72]. Atropine, verapamil and trifluoroperazine (TFP) were 
obtained from Sigma-Aldrich (St. Louis, MO, USA); J104129, ODQ, 
U-73122, S-Methylisothioures (S-Methy-U), L-NIO dehydrochloride 
(L-NIO), N-Propyl-L-arginine hydrochloride (N-PL) and L-NG-
monomethyl arginine citrate (L-NMMA) were from Tocris Cookson 
(Ellisville, MO, USA). Stock solutions were freshly prepared in the 
appropriate buffers. The drugs were diluted in a water bath to achieve 
the final concentrations stated in the text.
Patients: The subjects of this study were 30 pSS patients’ anti-Ro/
SSA positive and 30 healthy volunteers all female, (age 39-54 years) 
selected from the metropolitan area of Buenos Aires. The diagnosis of 
pSS fulfilled the criteria described by Vitali et al. [34] and was given by 
means of a positive biopsy with a score focus of 3.8 ± 0.07. 
Purification of Human IgG: The serum IgG fraction from patients 
with pSS and from normal individuals (control) was isolated using 
protein G affinity chromatography as described elsewhere [41]. Briefly, 
sera were loaded onto the protein G affinity column (Sigma-Aldrich, 
St Louis, MO, USA) equilibrated with 1 MTris-HCl (pH 8.0) and the 
columns were washed with 10 volumes of the same buffer. The IgG 
fraction was eluted with 100 mM glycine-HCl, pH 3.0, and immediately 
neutralized. The concentration and purification of IgG were determined 
using a radial immune diffusion assay.
Anti-M3 peptide IgG procedure: The IgG fraction from 30 patients 
with pSS and 30 healthy subjects was independently subjected to 
affinity chromatography on the synthesized peptide covalently linked 
to AffiGel 15 gel (Bio-Rad, Richmond, CA, USA) as described by Reina 
et al. [49]. Briefly, the IgG fraction was loaded onto the affinity column 
equilibrated with phosphate buffered saline (PBS). The non-peptide 
fraction was first eluted with the same buffer. Specific anti-peptide 
antibodies were then eluted with 3 M KSCN and 1 M NaCl, followed by 
immediate extensive dialysis against PBS. 
The IgG concentration of non-anti-peptide antibodies and 
specific anti-muscarinic receptor peptide antibodies was determined 
by a radial immunodiffusion assay. Their immunological reactivity 
against muscarinic receptor peptides was evaluated by ELISA. The 
concentration of the affinity-purified anti-M3 peptide IgG (1×10-8 M) 
increased optical density (mean OD ± SEM, 2.4 ± 0.2). 
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The non-anti-M3 peptide IgG fraction eluted from the column 
showed OD values (0.27 ± 0.06) similar to those of normal IgG from 
healthy individuals taken as control (0.26 ± 0.05). The normal IgG 
fraction purified by affinity column chromatography gave a negative 
result (0.30 ± 0.03). ELISA was performed as described previously [74].
ELISA: Fifty microliters of M3 synthetic peptide solution (20 μg/
ml) in 0.1 M Na2CO3 buffer, pH 9.6, was used to coat microtiter plates 
(NUNC, Kastrup, Denmark) at 4°C overnight. After blocking the wells, 
diluted sera from pSS patients and healthy individuals were added in 
triplicate and allowed to react with the peptide for 2 hour at 37°C. 
After the wells were thoroughly washed with 0.05% Tween 20 in 
a PBS, 100 μl of 1:6000 biotinylated goat anti-human IgG antibodies 
(Sigma Chemical Co., St. Louis, MO, USA) was added and incubated 
for 1 hour at 37°C. Then, a 1:6000 dilution of extravidin-alkaline 
phosphatase (Sigma) was allowed to react an extra 30 min at 37°C. After 
extensive washings, p-nitrophenylphosphate (1 mg/ml) was added as 
the substrate, and the reaction was stopped at 30 min. Finally, the plates 
were read at 405 nm and the results for each sample were expressed as 
the means ± SD of triplicate values.
PGE2 procedure: Serum PGE2 was measured by ELISA, carried out 
according to the manufacturer’s protocols (Biotrack Enzyme Immune 
Assay System, Amersham Bioscience, Piscateway, NJ, USA). 
The OD cutoff value of PGE2 was 4.4 ± 0.33 ng/ml. All serum 
samples were frozen promptly after collection and kept at -80ºC until 
used for PGE2 determination. The result is expressed as ng/ml.
Nitric oxide synthase (NOS) assay: NOS activity was measured 
in rat submandibular gland tissue by production of [U-14C]-citrulline 
from [U-14C]-arginine according to the procedure described for brain 
slices [77]. Briefly, after 20-min preincubation in KRB solution, tissues 
were transferred to 500 ml of prewarmed KRB equilibrated with 5% 
CO2 in O2 in the presence of [U-14C]-arginine (0.5 mCi). 
Drugs were added and the mixture incubated for 20 min under 
5% CO2 in O2 at 37°C. Tissues were then homogenized with an 
Ultraturrax homogenizer in 1 ml of medium containing 20 mM HEPES 
(pH 7.4), 0.5 mM ethyleneglycol tetra-acetic acid (EGTA), 0.5 mM 
ethylenediamine tetra-acetic acid (EDTA), 1 mM dithiothreitol, 1 mM 
leupeptin and 0.2 mM phenylmethylsulphonyl fluoride (PMSF) at 4°C. 
After centrifugation at 20,000×g for 10 min at 4°C, supernatants 
were applied to 2 ml columns of Dowex AG 50 WX-8 (sodium form). 
[14C]-citrulline was eluted with 3 ml of water and quantified by liquid 
scintillation counting. The results were expressed as picomol per gram 
tissue wet weight (pmol/g/tissue wet wt).
Cyclic nucleotides assay (cGMP): Rat submandibular gland (10 
mg) was incubated in 1 ml Krebs Ringer Buffer (KRB) for 30 min, and 
the anti-M3 mAChR peptide IgG was added in the last 15 min. When a 
blocker was used, it was added 25 min before the addition of the antibody. 
After incubation, submandibular gland tissue was homogenized in 2 mL 
of absolute ethanol and centrifuged (6000×g, 15 min, 4°C). 
Pellets were then re-homogenized in ethanol-water (2:1) and re-
centrifuged. The supernatant was collected and evaporated to dryness. 
Cyclic GMP in the residue was dissolved in 400 μl of 0.05 M sodium 
acetate buffer (pH 6.2). For the determination of nucleotide, we used 
ELISA employing the protocol for the production of cGMP from 
Amersham Biosciences (Piscataway, NJ, USA). Results are expressed as 
picomoles per milligram of wet weight of tissue (pmol/mg tissue wet 
weight).
mRNA isolation and cDNA synthesis: Total RNA was extracted 
from rat submandibular gland slices by homogenization using 
guanidiniumisothiocyanate method. As previously described [41], a 
20-μl reaction mixture contained 2 ng of mRNA, 20 units of RNase 
inhibitor, 1 mMdNTPs and 50 units of Moloney murine leukemia 
virus reverse transcriptase (Promega, Madison, WI, USA). First-strand 
cDNA was synthesized at 37°C for 60 min.
PCR procedures: NOS isoform-mRNA levels were determined 
by a method that involves simultaneous co-amplification of both the 
target cDNA and a reference template (MIMIC) with a single set of 
primers. MIMIC for eNOS, nNOS and glyceraldehyde-3-phosphate 
dehydrogenase (G3PDH) was constructed using a PCR MIMIC 
construction kit (Clontech Laboratories, Palo Alto, CA). 
Each PCR MIMIC consists of a heterologous DNA fragment with 5’ 
and 3’-end sequences that recognized by a pair of gene-specific primers. 
Sizes of PCR MIMIC were distinct from those of native targets. The 
sequence of oligonucleotideprimer pairs used for construction of 
MIMIC and amplification of NOS isoforms and G3PDH mRNA is 
listed in Table 1.
Aliquots were taken from pooled first-strand cDNA from the same 
group and constituted one sample for PCR. A series of 10-fold dilutions 
of known concentrations of the MIMIC were added to PCR amplification 
reactions containing the first-strand cDNA. PCR MIMIC amplification 
was performed in 100 µl of a solution containing 1.5 mM MgCl2, 0.4 
µM primer, dNTPs, 2.5 U Taq DNA polymerase and 0.056 μMTaq Start 
antibody (Clontech Laboratories). After initial denaturation at 94°C 
for 2 min, the cycle condition was 30 s of denaturation at 94°C, 30 s 
of annealing at 60°C and 45 s for enzymatic primer extension at 72°C 
for 45 cycles for NOS isoforms. The internal control was the mRNA 
of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase 
(G3PDH). 
PCR amplification was performed with initial denaturation at 94°C 
for 2 min followed by 30 cycles of amplification. Each cycle consisted 
of 35 s at 94°C, 35 s at 58°C and 45 s at 72°C. Samples were incubated 
for an additional 8 min at 72°C before completion. PCR products were 
subjected to electrophoresis on ethidium bromide-stained gels. Band 
intensity was quantitated by densitometry using NIH Image software. 
Levels of mRNA were calculated from the point of equal density of the 
sample and MIMIC PCR products [41]. 
NOS isoforms mRNA levels were normalized with the levels of 
G3PDH mRNA present in each sample, which served to control for 
Gene Product Sense Antisense Predicted size (bp)
iNOS 5´ GAT CAA TAACCT GAA GCC CG  3´ 5´ GCC CTT TTT TGC TCC ATA GG 3´ 578
nNOS 5´ GCGGA GCAGA GCGGC CTTAT  3´ 5´ TTTGGT GGGAG GACCG AGGG  3´ 240
eNOS 5´ CCGCA CTTCT GTGCC TTTGC TC3´ 5´GCTCG GGTGG ATTTGC TGCTCT 3´ 360
g3pdh 5´ ACCAC AGTCCA TGCCAT CAC  3´ 5´ TCCAC CACCC TGTTG CTGTA  3´ 452
Nitric oxide synthase (NOS) isoforms and glyceraldehydes-3-phosphate dehydrogenase (g3pdh)
Table 1: Oligonucleotides of primers for PCR.
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variations in RNA purification and cDNA synthesis. Relative mRNA 
expression of nNOS and eNOS were compared with those from the 
respective normal individuals and pSS patients reported as a percentage 
of normal.
Statistical analyses: The Student’s “t” test for unpaired values was 
used to determine the level of significance. If multiple comparisons 
were necessary, after analysis of variance, the Student-Newman-Keuls 
test was applied. Differences between means were considered significant 
if P<0.05.
Results
Figure 1 shows the immunoreactivity of sera (A), pSSIgG (B) 
and pSSIgG anti M3mAChR synthetic peptide (pSSIgG anti M3) (C) 
of pSS patients and healthy individuals against M3 synthetic peptide. 
Figure 1: Effect of serum, IgG and IgG anti M3 autoantibodies from patients with primary Sjögren syndrome (pSS) evaluated by enzyme immunoassay (ELISA). UPPER 
PANEL: Dose-response curve of different serum dilution (A), different concentration of pSS IgG (B) and different concentration of pSS IgG anti M3 (C) autoantibodies of 
pSS patients (●) against M3 mAChR synthetic peptide.  The values of normal sera and normal IgG and normal IgG anti M3 (■) is also shown. *P<0.0001 versus serum, 
IgG and IgG anti M3 of normal individuals.  MIDDLE PANEL: Scatterogram showing immunoreactivity of pSS serum (D), pSS IgG (E) and pSS IgG anti M3 (F) of SS 
patients (●) and normal individuals (■) against M3 synthetic peptide. The individual optical density (OD) values for each serum sample or pSS IgG or pSS IgG anti M3 
were taken from 30 normal individuals and 30 patients with pSS. OD values more than 2 SD above the normal mean, were taken as positive. Cut off value of OD: D= 
0.25 ± 0.05, E= 0.24 ± 0.06 and F= 0.18 ± 0.03 respectively. LOWER PANEL: Influence of 1x10-6 M atropine (unspecific mAChR antagonist), 1x10-8 M J104129 (specific 
M3 mAChR antagonist) and 5x10
-7 M anti M3 synthetic peptide on the maximal dilution or concentration of serum (G), pSS IgG (H) and pSS IgG anti M3 (I) respectively. 
The values of normal sera and normal IgG and normal IgG anti M3 is also shown. Values are mean ± SEM from a pool of 30 pSS patients and 30 normal individuals. 
*P< 0.0001 versus normal (n) serum or IgG; **P<0.001 versus pSS serum or pSS IgG. All the experiments were performed by duplicates.
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We can see that the optical density values (OD) of pSSIgG anti M3 was 
significantly higher than those of pSSIgG and pSS serum. Serum, IgG 
and pSSIgG anti M3 of healthy individuals showed similar OD values, 
which are significantly lower than those of SS patients.
Scatterogram (Figure 1) shows the immunoreactivity of pSS serum 
(D), pSSIgG (E) and pSSIgG anti M3 (F) of pSS patients and normal 
individuals against M3 synthetic peptide. The immunoreactivity of 
serum, pSSIgG and pSSIgG anti M3 was significantly (P<0.0001) higher 
than that of normal individuals used as control.The specificity of the 
reaction was assessed by the ability of the M3 synthetic peptide, atropine 
(unspecific muscarinic antagonist) and J104129 (specific M3 muscarinic 
antagonist) to inhibit the reaction when serum or IgG was incubated 
with salivary gland membrane mAChR (Figure 1G-I). 
Figure 2A shows the ability of pSSIgG anti M3 to stimulate NOS 
activity in a concentration-dependent manner. L-NMMA 5×10-5 M 
blocked the action of pSSIgG anti M3 on NOS activity. Figure 2B (black 
column) shows the maximal effect of 1×10-8 M of pSSIgG anti M3 alone 
(b) or in the presence of the 1×10-5 M L-NMMA (c) or L-NMMA plus 
1×10-4 M L-arginine (d) (reverse experiment). Basal (control) values are 
also shown (a). The IgG anti M3 of normal individuals (white column) 
used as a control, is shown (Figure 2Ba-d). 
The particular NOS isoforms enzymes which participate in the 
generation of endogenous nitric oxide (NO), can be seen in Figure 3. 
The specific inhibition of iNOS with S-Methylisothioures (S-Methy-U) 
prevented the stimulation of NOS activity by the pSSIgG anti M3. The 
inhibition of eNOS by L-NIO dehydrochloride (L-NIO) and nNOS by 
N-Propyl-L-arginine hydrochloride (N-PL) were without any effect 
being iNOS the only isoform able to impair the stimulation of NOS 
activity by the autoantibody. The table inserted in this figure, shows the 
Figure 2: A: Concentration-response curve of pSS IgG anti M3 (●) and normal IgG anti M3 (■) on nitric oxide synthase (NOS) activity from rat submandibular gland. 
Basal value (b) corresponds to NOS activity after 60 min of incubation [254 ± 19 pmol/g tissue wet wt]. Values are mean ± SEM of five experiments in each group 
performed in duplicate. *P<0.0001 versus 5x10-5 M L-NMMA + pSS IgG anti M3.  B: Preparations [white columns: normal IgG anti M3 (n IgG anti M3) and black columns 
pSS IgG anti M3] were incubated for 60 min with 1x10-8 M pSS IgG anti M3 in absence (b) or in presence (c) of 5x10
-5 M L-NMMA and L-NMMA plus 1x10-4 M L-arginine 
(d). Basal values before the addition of any antibody or drugs (a). Values are mean ± SEM of five experiments in each group performed in duplicate. *P<0.0001 versus 
n IgG anti M3, **P<0.001 versus nIgG anti M3.
Figure 3: Upper panel: Effect of pSS IgG anti M3 on NOS activity in salivary gland. Submandibular gland were incubated with increasing concentrations of pSS IgG 
anti M3 alone (●) or in the presence of 1x10
-5 M (S) Methylisothioures (S-Methy-U) (♦), 5x10-6 M L-NIO dehydrochloride (L-NIO) (▲) or 5x10-6 M N-Propyl-L-arginine 
hydrochloride (N-PL) (▼). *P<0.0001 versus pSS IgG anti M3. Values are mean ± SEM of five experiments performed in duplicate. Lower panel: Table insert in Figure 
showed the effect of normal IgG anti M3 (n IgG anti M3) alone or in the presence of different NOS isoforms inhibitors taken as control values.
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values of NOS activity in the presence of normal IgG anti M3 and the 
isoforms inhibitors taken as a control. These results indicate that the 
pSSIgG anti M3 stimulated NOS activity is a result of the increment in 
NO with major participation of iNOS.
In order to discern, which endogenous mechanisms (second 
messengers) are implicated in pSSIgG anti M3 NOS activation and 
the generation of NO production, several inhibitors of this enzymatic 
pathways were used. It can be seen in Figure 4 that the stimulation 
of NOS activity by the pSSIgG anti M3 was inhibited by M3 synthetic 
peptide (A, B, C), S-Methyl-U and U-73122 (A), L-NIO and verapamil 
(B) and N-PL and TFP (C). These results indicate that pSSIgG anti M3-
M3mAChR stimulation may trigger the production of NO synthesis in 
submandibular salivary glands by iNOS isoforms dependent on PLC 
activation. NO exerts its effects mainly by activating soluble guanylyl 
cyclases in the presence of the pSSIgG anti M3 in a concentration 
dependent manner, increasing cGMP synthesis in rat submandibular 
gland (Figure 5). 
The increment in cGMP production is inhibited by the specific 
soluble guanylylcyclases inhibitor (ODQ) and the IgG anti M3 of 
normal individuals was without effect in our system (A). The NO-
Figure 4: Effect of pSS IgG anti M3 (black column) on NOS activity in submandibular gland.  The glands were incubated with 1x10-8 M  pSS IgG anti M3 alone or in the 
presence of 1x10-4 M synthetic M3 peptide, 1x10
-5 M S-Methyl-U and  5x10-6 M U-73122 (A), 1x10-4 M synthetic M3 peptide, 5x10-6 M L-NIO and  5x10-5 M verapamil 
(B) and 1x10-4 M synthetic M3 peptide, 5x10-6 M N-PL and  5x10-6 M TFP (C). Basal values (white column) without any additions and n IgG anti M3 were also shown. 
Values are mean ± SEM of six experiments performed in duplicate. *P<0.001 versus basal and n IgG anti M3, **P<0.001 versus pSS IgG anti M3 alone.
Figure 5: Effects of pSS IgG anti M3 in salivary glands. (A) Submandibular glands were incubated with increasing concentration of pSS IgG anti M3 alone (●) or in the 
presence of ODQ (1x10-7 M) (▲) and n IgG anti M3 (■). Values represent the mean ± SEM of five experiments performed in duplicate. *P > 0.0001 versus pSS IgG anti 
M3 + ODQ. (B) Action of pSS IgG anti M3 on cyclic GMP (cGMP) accumulation rat submandibular gland were incubated with 1x10
-8 M of pSS IgG anti M3 alone or in the 
presence of different inhibitors: U-73122 at 5x10-6 M, verapamil at 5x10-5 M and TFP at 5x10-6 M. Results are mean ± SEM of four experiments performed in duplicate 
in each groups. *P<0.0001 versus basal and n IgG anti M3, **P<0.001 versus pSS IgG anti M3.
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cGMP accumulation is mediated by the effect of PLC, calcium influx 
and calcium/calmodulin activation (B) since the NO-cGMP increment 
is blunted by U-73122, verapamil and TFP. To settle the role of NOS 
isoforms in the action of pSSIgG anti M3 on rat submandibular gland 
M3mAChR activation, specific primers for iNOS (A), nNOS (B) and 
eNOS (C) were used. 
Figure 6 shows RT-PCR products and semi-quantitative RT-PCR 
analysis demonstrating that the pSSIgG anti M3 1×10-8 M stimulation 
for one hour increase NOS mRNA levels with no modification of NOS 
mRNA levels by normal IgG anti M3 (control). The same figure shows 
that M3 synthetic peptide, S-Methil-U, L-NIO and N-PL attenuate the 
stimulatory effect of pSSIgG anti M3 on NOS mRNA levels. The internal 
control for the mRNA of the housekeeping gene of glyceraldehyde-
3-phosphate- dehydrogenase (g3pdh) is shown. Regarding mRNA 
expression these results demonstrate that pSSIgG anti M3 acts as an 
inducer of iNOS mRNA without a significative action on nNOS and 
eNOS mRNA levels.
The sequence of oligonucleotide primers pairs used is listed in Table 
1. The relative mRNA expression of iNOS, nNOS and eNOS in each 
group was compared to those of the corresponding normal group and 
reported as a percentage.
The fact that pSSIgG anti M3 antibody induces iNOS activity and 
expression, tempts us to speculate that the antibody can have direct 
influence on rat submandibular gland through the production of a large 
amount of pro-inflammatory substances and cytotoxic NO by means 
of the activation of mAChR subtype M3. In turn, NO could be said to 
contribute to immune inflammation at the level of rat submandibular 
gland, regulating not only the degree of inflammation but also 
decreasing salivary secretion. All of these facts are the consequence 
of an abnormal glandular parasympathetic function (parasympathetic 
dysautonomia) with the participation of PLC (IP3), calcium influx and 
calcium/calmodulin activation.
Conclusion
The present study suggests a complex interplay between different 
factors involved in innate and adaptive immunity. The presence of 
anti-M3mAChR peptide IgG and the enhancement of NOS activity 
and its expression could provide a link between autoimmunity and 
parasympathetic system in Sjögren syndrome. Further, the early 
agonist-promoting activation of salivary gland M3mAChR initiated 
by cholinergic autoantibodies binds to and persistently activates 
cholinoceptors, resulting in the production of large amounts of 
proinflammatory substances, contributing to inflammation. 
The cholinergic agonistic activity displayed by anti-M3mAChR 
peptide IgG could subsequently induce desensitisation, internalisation 
and/or intracellular degradation of glandular M3mAChR. This would 
lead to a progressive reduction in the surface expression and activity of 
glandular M3mAChR, resulting in xerostomy, xerophthalmia and other 
general parasympathetic symptoms in SS patients.
In this paper we propose a model to explain the mechanism 
whereby pSSIgG stimulate rat submandibular gland mAChR subtype 
M1 and M3. According to our model pSSIgG acting on frontal cerebral 
cortex and submandibular gland mAChR subtype M1 and M3 activate 
the Gβγ subunit protein. 
The activation of Gβγ leads to the activation of caspase-8 and the 
Gαs/q subunit provoking JNK phosphorylation and increasing MMP-3 
production, which contributes to increase PGE2 levels. Gαs/q subunit 
itself also activates PLC with the production of IP3 (that in turn increase 
intracellular calcium concentration) and DAG (that in turn activating 
PKC activity) and provokes the decrement of the salivary mucin leading 
to the reduction in the protection of the oral tissues. 
Activation of adenylatecyclase leads to cAMP accumulation with 
an increase in the efflux of extracellular calcium. This, in turn, increases 
intracellular calcium concentrations; and induces their binding to the 
calcium/calmodulin complex (CaM). The CaM complex increases 
nitric oxide synthase activity through the inducible isoform (iNOS) 
that, in turn, increases Nitric Oxide (NO) production, triggering cyclic 
GMP (cGMP) accumulation. 
The overproduction of NO also triggers the induction of iNOS 
Figure 6: Action of pSS IgG anti M3 on semi-quantitative RT-PCR analysis for iNOS (A), nNOS (B) and eNOS (C) mRNA levels from submandibular gland incubated 
during one hour with 1x10-8 M pSS IgG anti M3 in absence or in presence of 1x10
-4 M synthetic M3 peptide and 1x10
-5 M S-Methyl-U (A) or 1x10-4 M synthetic M3 peptide 
and 5x10-6 M L-NIO (B) or 1x10-4 M synthetic M3 peptide and 5x10
-6 M N-PL (C). Basal value corresponds to mRNA level after one hour incubation without antibodies or 
drug inhibitors. Normal IgG anti M3 (1x10
-8 M) are also shown. The RT-PCR products obtained were: *P<0.0001 versus nIgG anti M3 and basal and **P<0.001 versus 
pSS IgG anti M3. The internal control for the mRNA of the housekeeping gene of glyceraldehyde-3-phosphate-dehydrogenase (g3pdh) is shown.
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mRNA levels. The rise in cytosolic calcium activates phospholipase 
A2 (PLA2) with activation of COX-2, which results in PGE2 generation 
with an increased production of cAMP levels. The generation of 
PGE2 induces the inhibition of membrane Na+-K+-ATPase activity 
accompanied by an increment of cAMP accumulation. The activation 
of caspases-8 and -9 activates caspase-3, leading to apoptosis. Figure 
7 below depicts the previously related facts (findings and shadings) 
indicates direct mechanisms (filled arrows) and indirect mechanisms 
(dotted arrows).
Perspective
The activation of glandular M3mAChR by the serum autoantibody 
present in patient with SS induces changes in the production of the 
second messengers. These changes are generated by the activation 
and binding of the glandular cholinoceptor. A synthetic M3 peptide 
is able to block all actions generated by the antibody on glandular 
cholinoceptors. This being the case, the synthetic M3 peptide could be 
used as a therapeutic mean. Such a therapeutic mean, would capture the 
circulating mAChR autoantibodies thus reducing the destruction of the 
exocrine glands, the subsequent inflammatory process and indirectly 
the sicca symptoms of SS.
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